Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-24 17:45 |
Availability of Preparatory Documents for the Combined General Meeting of May 1…
|
English | 187.9 KB | ||
| 2024-04-11 19:05 |
Document d'enregistrement Universel 2023
|
French | 7.6 MB | ||
| 2024-04-11 19:05 |
Document d'enregistrement Universel 2023
|
French | 7.6 MB | ||
| 2024-04-11 17:45 |
Availability of Transgene's 2023 Universal Registration Document
|
English | 175.3 KB | ||
| 2024-04-11 17:45 |
MIse à disposition du document d'enregistrement universel 2023 de Transgene
|
French | 171.9 KB | ||
| 2024-04-11 12:47 |
Transgene DEU 2023 ESEF
|
French | 7.6 MB | ||
| 2024-04-11 12:47 |
Transgene DEU 2023 ESEF
|
French | 7.6 MB | ||
| 2024-04-09 17:45 |
Transgene et NEC présentent les premiers signes de bénéfice clinique de leur va…
|
French | 438.8 KB | ||
| 2024-04-09 17:45 |
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine,…
|
English | 429.8 KB | ||
| 2024-03-27 17:45 |
Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle …
|
French | 349.4 KB | ||
| 2024-03-27 17:45 |
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Sch…
|
English | 346.0 KB | ||
| 2024-03-18 17:45 |
Transgene annonce ses prochaines rencontres avec les investisseurs
|
French | 214.2 KB | ||
| 2024-03-18 17:45 |
Transgene Announces Upcoming Investor Meetings
|
English | 204.1 KB | ||
| 2024-03-06 07:30 |
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at A…
|
English | 370.4 KB | ||
| 2024-03-06 07:30 |
Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à…
|
French | 274.6 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
